This article provides a comprehensive overview of the innovative drug sector, explaining its core definition, recent market drivers, key investment indices, and the outlook for the ongoing rally.
What Defines an Innovative Drug?
What distinguishes a "generic drug" from an "innovative drug"? This is not merely a semantic difference; in the capital markets, the distinction is profound. Generic drugs involve "contract manufacturing"—replicating existing inventions to earn modest returns. In contrast, innovative drugs involve discovering new targets and mechanisms from the ground up, achieving "zero-to-one" breakthroughs, and generating profits from intellectual property and global market access.
The industrial characteristics of innovative drugs are defined by three critical attributes. First, the research and development cycle is lengthy. Bringing a new drug from discovery to market typically takes 10 to 15 years on average, with costs exceeding $1 billion, representing a classic model of "long cycle, high investment, and high risk." Second, there is a patent protection period. Upon approval, a drug is granted a 20-year patent, allowing for exclusive sales and profits derived from this monopoly. Third, the business model is globally replicable. Once approved by regulatory bodies like the U.S. FDA, the drug can be marketed worldwide, offering a vast, global market with a very high ceiling.
In summary, innovative drugs represent a high-tech, high-risk, and high-reward sector. Investing in it is fundamentally a bet on the future of cutting-edge biotechnology, rather than a simple defensive play.
Catalysts Behind the Recent Surge
Since June 18th, the innovative drug sector, represented by indices like the CSI Innovative Drug Index, has seen a sustained upward trend, with clear signs of capital returning and gradually warming market sentiment. Just a month ago, this was a neglected sector. The dramatic shift in market attitude within weeks can be attributed to several key factors.
Firstly, significant supportive policies have been introduced. On June 29th, the medical insurance authority announced a major policy: the "Medical Insurance + Commercial Insurance" dual catalog system, which for the first time separately listed a commercial insurance catalog for innovative drugs. This provides an additional payment channel for high-priced innovative drugs, greatly alleviating market concerns over drastic price negotiations. Coupled with the implementation of a "pre-submission" mechanism, the time from drug approval to inclusion in the reimbursement catalog has been significantly shortened from 1-2 years. This wave of policy benefits directly ignited market enthusiasm.
Secondly, capital is rotating from high-valuation sectors to seek safe havens. As high-flying tech sectors like AI have recently corrected, some capital has flowed out of crowded trades and moved into the pharmaceutical sector, which was at a valuation bottom.
Thirdly, overseas business development and licensing deals are setting records. In the first quarter of 2026, the total value of Chinese innovative drug BD transactions surged to $61.4 billion, already surpassing the full-year total for 2024 and approaching half of the 2025 level. This indicates that China's innovative drug pipeline is increasingly gaining global transactional value.
Navigating the Array of Innovative Drug Indices
Many investors express interest in the sector but are confused by the variety of fund names and indices. To clarify, here is a comparison of three mainstream innovative drug indices. The CSI Innovative Drug Index is suitable for those seeking pure exposure to A-share innovative drug companies. The SHS Innovative Drug Index is more appropriate for investors bullish on Hong Kong-listed biotech firms. For those preferring the higher volatility and potential returns associated with the STAR Market, the CSI STAR Innovative Drug Index is a solid choice.
Assessing the Sustainability of the Rally
In the short term, the downside appears limited. The easing of centralized procurement pressure, the implementation of the commercial insurance catalog, and significantly faster market access—these three institutional reforms have opened space for valuation recovery in innovative drugs. Combined with support from both valuation and positioning lows, it suggests that even if short-term volatility occurs, the sector's downside is relatively contained.
In the medium term, a fundamental inflection point is being confirmed. The explosion in BD deal values, the ongoing readout of overseas clinical trial data, and the continuous receipt of milestone payments from pharmaceutical partnerships—these tangible performance drivers constitute the core force propelling the rally from a "policy-driven rebound" towards an "earnings-driven reversal."
For future operations, investors can focus on tracking three key clues: the readout of data from overseas clinical trial endpoints for core drug pipelines, the realization of milestone payments from overseas partnerships, and whether institutional capital is gradually shifting from an "underweight" stance to "replenishing" positions.
Risk Disclaimer
The views expressed are for reference only and may change with market conditions, constituting neither investment advice nor any promise. Mentioned indices are for reference only and do not constitute investment advice or a prediction or guarantee of fund performance. Index data is sourced from index compilation methodologies. Before purchasing any related fund products, please carefully read the fund's legal documents such as the Fund Contract and Prospectus, and select products matching your risk tolerance. Funds carry risks, and investment requires caution.